Skip to main content
Top
Published in: Journal of Gastroenterology 4/2011

01-04-2011 | Review

Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review

Authors: Alexander C. Ford, Nicholas J. Talley

Published in: Journal of Gastroenterology | Issue 4/2011

Login to get access

Abstract

Background

The causes of irritable bowel syndrome (IBS) remain obscure. Some investigators have proposed chronic low-grade mucosal inflammation as a potential etiological factor. We performed a systematic review to examine this issue in detail.

Methods

MEDLINE, EMBASE, and EMBASE classic were searched up to December 2010 to identify studies of case–control design applying tests for low-grade inflammation to either full-thickness intestinal or endoscopic mucosal biopsies from patients with IBS. Controls were required to be healthy individuals, or asymptomatic patients undergoing investigation for reasons other than the reporting of upper or lower gastrointestinal symptoms. Individual study results were summarized descriptively.

Results

The literature search identified 1388 citations, of which 16 studies were eligible for inclusion. Individual study results were diverse, partly as a consequence of the different surrogate markers for inflammatory mechanisms studied. Mast cells, T lymphocytes, B lymphocytes, and mucosal cytokine production all appeared altered among cases with IBS in individual studies, while no study demonstrated a significant difference in numbers of plasma cells, neutrophils, or eosinophils. Some studies suggested a relationship between mast cell abnormalities and symptom severity and frequency, as well as co-existent fatigue and depression. Studies were limited by the lack of comparability of controls, and the fact that most were conducted in highly selected groups of patients with IBS.

Conclusions

Low-grade mucosal inflammation, particularly mast cell activation, may be a contributory factor in the pathogenesis of IBS. Mast cell stabilizers warrant further assessment as a potential therapy in the condition.
Literature
1.
go back to reference Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.PubMedCrossRef Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.PubMedCrossRef
2.
go back to reference Agreus L, Talley NJ, Svardsudd K, et al. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. Scand J Gastroenterol. 2000;35:142–51.PubMedCrossRef Agreus L, Talley NJ, Svardsudd K, et al. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. Scand J Gastroenterol. 2000;35:142–51.PubMedCrossRef
3.
go back to reference Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther. 2004;20:339–45.PubMedCrossRef Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther. 2004;20:339–45.PubMedCrossRef
4.
go back to reference Hungin APS, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–50.PubMedCrossRef Hungin APS, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–50.PubMedCrossRef
5.
go back to reference Mearin F, Badia X, Balboa A, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol. 2001;36:1155–61.PubMedCrossRef Mearin F, Badia X, Balboa A, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol. 2001;36:1155–61.PubMedCrossRef
6.
go back to reference Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–80.PubMedCrossRef Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–80.PubMedCrossRef
7.
go back to reference Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229–39.PubMedCrossRef Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229–39.PubMedCrossRef
8.
go back to reference Halder SLS, Locke GR III, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology. 2007;133:799–807.PubMedCrossRef Halder SLS, Locke GR III, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology. 2007;133:799–807.PubMedCrossRef
9.
go back to reference Kalantar JS, Locke GR, Zinsmeister AR, et al. Familial aggregation of irritable bowel syndrome: a prospective study. Gut. 2003;52:1703–7.PubMedCrossRef Kalantar JS, Locke GR, Zinsmeister AR, et al. Familial aggregation of irritable bowel syndrome: a prospective study. Gut. 2003;52:1703–7.PubMedCrossRef
10.
go back to reference Stanghellini V, Tosetti C, Barbara G, et al. Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Am J Gastroenterol. 2002;97:2738–43.PubMedCrossRef Stanghellini V, Tosetti C, Barbara G, et al. Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Am J Gastroenterol. 2002;97:2738–43.PubMedCrossRef
11.
go back to reference Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24:405–11.PubMedCrossRef Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24:405–11.PubMedCrossRef
12.
go back to reference Moriarty KJ, Dawson AM. Functional abdominal pain: further evidence that whole gut is affected. Br Med J. 1982;284:1670–2.CrossRef Moriarty KJ, Dawson AM. Functional abdominal pain: further evidence that whole gut is affected. Br Med J. 1982;284:1670–2.CrossRef
13.
go back to reference Trimble KC, Farouk R, Pryde A, et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995;40:1607–13.PubMedCrossRef Trimble KC, Farouk R, Pryde A, et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995;40:1607–13.PubMedCrossRef
15.
go back to reference Collins SM. Is the irritable gut an inflamed gut? Scand J Gastroenterol. 1992;192(suppl):102–5.CrossRef Collins SM. Is the irritable gut an inflamed gut? Scand J Gastroenterol. 1992;192(suppl):102–5.CrossRef
16.
go back to reference Marshall JK, Thabane M, Borgaonkar MR, et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol. 2007;5:457–60.PubMedCrossRef Marshall JK, Thabane M, Borgaonkar MR, et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol. 2007;5:457–60.PubMedCrossRef
17.
go back to reference Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59:605–11.PubMedCrossRef Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59:605–11.PubMedCrossRef
18.
go back to reference Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one year follow-up cohort study. Gastroenterology. 2005;(129):98–104.CrossRef Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one year follow-up cohort study. Gastroenterology. 2005;(129):98–104.CrossRef
19.
go back to reference Tornblom H, Holmvall P, Svenungsson B, et al. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol. 2007;5:461–4.PubMedCrossRef Tornblom H, Holmvall P, Svenungsson B, et al. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol. 2007;5:461–4.PubMedCrossRef
20.
go back to reference Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096–101.PubMedCrossRef Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096–101.PubMedCrossRef
21.
go back to reference Mearin F, Perello A, Balboa A, et al. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol. 2009;44:1173–85.PubMedCrossRef Mearin F, Perello A, Balboa A, et al. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol. 2009;44:1173–85.PubMedCrossRef
22.
go back to reference Weston AP, Biddle WL, Bhatia PS, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38:1590–5.PubMedCrossRef Weston AP, Biddle WL, Bhatia PS, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38:1590–5.PubMedCrossRef
23.
go back to reference Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRef Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRef
24.
go back to reference Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.PubMedCrossRef Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.PubMedCrossRef
25.
go back to reference Bian ZX, Li Z, Huang ZX, et al. Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients. J Gastroenterol. 2009;44:666–74.PubMedCrossRef Bian ZX, Li Z, Huang ZX, et al. Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients. J Gastroenterol. 2009;44:666–74.PubMedCrossRef
26.
go back to reference Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636–47.PubMedCrossRef Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636–47.PubMedCrossRef
27.
go back to reference Chadwick V, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778–83.PubMedCrossRef Chadwick V, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778–83.PubMedCrossRef
28.
go back to reference Choung RS, Faubion WA, Saito YA et al. Cytokine expression in colonic mucosa and plasma in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2010;22 (Suppl S1):57. Choung RS, Faubion WA, Saito YA et al. Cytokine expression in colonic mucosa and plasma in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2010;22 (Suppl S1):57.
29.
go back to reference Coeffier M, Gloro R, Boukhettala N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol. 2010;105:1181–8.PubMedCrossRef Coeffier M, Gloro R, Boukhettala N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol. 2010;105:1181–8.PubMedCrossRef
30.
go back to reference Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392–400.PubMedCrossRef Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392–400.PubMedCrossRef
31.
go back to reference Forshammar J, Isaksson S, Strid H, et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1461–6.PubMedCrossRef Forshammar J, Isaksson S, Strid H, et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1461–6.PubMedCrossRef
32.
go back to reference Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203–9.PubMedCrossRef Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203–9.PubMedCrossRef
33.
go back to reference Lee KJ, Kim YB, Kim JH, et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23:1689–94.PubMedCrossRef Lee KJ, Kim YB, Kim JH, et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23:1689–94.PubMedCrossRef
34.
go back to reference MacSharry J, O’Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1467–76.PubMedCrossRef MacSharry J, O’Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1467–76.PubMedCrossRef
35.
go back to reference O’Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12:449–57.PubMedCrossRef O’Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12:449–57.PubMedCrossRef
36.
go back to reference Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57:468–73.PubMedCrossRef Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57:468–73.PubMedCrossRef
37.
go back to reference Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123:1972–9.PubMedCrossRef Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123:1972–9.PubMedCrossRef
38.
go back to reference Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia, and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765–73.PubMedCrossRef Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia, and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765–73.PubMedCrossRef
39.
go back to reference Lijmer JG, Mol BW, Heisterkamp S. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061–6.PubMedCrossRef Lijmer JG, Mol BW, Heisterkamp S. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061–6.PubMedCrossRef
40.
go back to reference Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20:1317–22.PubMedCrossRef Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20:1317–22.PubMedCrossRef
41.
go back to reference Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.PubMedCrossRef Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.PubMedCrossRef
42.
go back to reference Ford AC, Marwaha A, Lim A, et al. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8:401–9.PubMedCrossRef Ford AC, Marwaha A, Lim A, et al. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8:401–9.PubMedCrossRef
43.
go back to reference Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:834–42.PubMedCrossRef Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:834–42.PubMedCrossRef
44.
go back to reference Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59:1213–21PubMedCrossRef Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59:1213–21PubMedCrossRef
Metadata
Title
Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review
Authors
Alexander C. Ford
Nicholas J. Talley
Publication date
01-04-2011
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 4/2011
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-011-0379-9

Other articles of this Issue 4/2011

Journal of Gastroenterology 4/2011 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Alcohol drinking patterns and the risk of fatty liver in Japanese men

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.